Inmune Bio Q2 2026: Cash Drops to $18.4M, Going Concern Warning Reiterated as CORDStrom Regulatory Push Begins
INMB sits 73% above its 52-week low of $1.09 on light trading volume (0.3× avg).
Summary
Inmune Bio's Q2 2026 10-Q shows cash declining to $18.4M with a reiterated going concern warning, offset by progress toward CORDStrom regulatory filings and non-dilutive R&D tax credit receipts.
Key Events · Earnings and Guidance · INMB
-
Going Concern Warning Reiterated
Management states there is substantial doubt about the company's ability to continue as a going concern, with insufficient liquidity to sustain operations through one year from the issuance date. Cash and cash equivalents fell to $18.4 million at June 30, 2026, from $24.8 million at year-end 2025.
-
Cash Burn and Financing
Net cash used in operating activities was $6.6 million for H1 2026. The company raised $0.6 million from ATM sales (370,417 shares at avg $1.63) and $0.9 million from a warrant inducement (674,155 warrants exercised at $1.40). Subsequent to quarter-end, an additional 100,000 shares were sold at $2.09 for $0.2 million.
-
R&D Tax Credits Provide Non-Dilutive Cash
The company received $4.4 million in R&D tax credit reimbursements during H1 2026 ($3.6M from Australia, $0.8M from UK). An additional $4.2 million was received from Australia in July 2026, strengthening near-term liquidity.
-
CORDStrom Regulatory Submissions Planned
Inmune Bio plans to file a Marketing Authorization Application for CORDStrom in the UK by late Q3 or early Q4 2026, followed by an EU submission in early 2027 and a US BLA thereafter. No revenue is expected in the near term.
Analysis · INMB · Life Sciences
Inmune Bio's cash runway is shrinking fast — $18.4 million at June 30, down from $24.8 million at year-end, with a $6.6 million operating cash burn in the first half. Management again warns there is substantial doubt about the company's ability to continue as a going concern, projecting insufficient liquidity to fund operations for the next year. The company is relying on its ATM program (which raised just $0.6 million in H1 at an average $1.63 per share) and warrant inducements to stay afloat. On the positive side, CORDStrom is advancing toward regulatory submissions in the UK, EU, and US, and the company received $4.4 million in R&D tax credits in H1 plus another $4.2 million in July. The expanded stock incentive plan adds potential dilution. This filing underscores the race between regulatory progress and cash depletion.
At the time of this filing, INMB was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $1.09 to $2.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.